Herbert Raymond McMaster - 26 Aug 2021 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Director
Signature
/s/ Herbert R. McMaster
Issuer symbol
NRXP
Transactions as of
26 Aug 2021
Net transactions value
-$23,141
Form type
4
Filing time
02 Nov 2021, 16:07:26 UTC
Previous filing
22 Jun 2021
Next filing
21 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRXP Common Stock Options Exercise $40,626 +18,300 $2.22* 18,300 26 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Employee Stock Option (Right to buy) Conversion of derivative security $63,767 -28,724 -64% $2.22* 16,362 26 Aug 2021 Common Stock 28,724 $2.22 Direct F1
transaction NRXP Restricted Stock Units Award $0 +10,424 $0.000000 10,424 26 Aug 2021 Common Stock 10,424 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are fully vested.
F2 Shares and restricted stock units acquired pursuant to the exercise of 28,724 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 18,300 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 10,424 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.